

Cynthia Ma¹, Pat W. Whitworth², Svetislava Vukelja³, Carl Gray⁴, Sami Diab⁵, Jennifer Crozier⁶, Julian Berrocal⁷, Mehran Habibi⁸, Adam Brufsky⁹, Robert Maganini¹⁰, Gordan Srkalovic¹¹, Manojkumar Bhupathi¹², Trevor Feinstein¹³, Joyce O'Shaughnessy¹⁴, Julie Barone¹⁵, Esther Rehmus¹⁶, Laura Lee¹⁷, Victoria Poillucci¹⁸, Holly Nguyen¹⁸, Lisa Blumencranz¹⁸, William Audeh¹⁸, FLEX Investigators Network

1. Washington University School of Medicine, St. Louis, MO; 2. Nashville Breast Center, Nashville, TN; 3. Texas Oncology-Tyler, US Oncology, Tyler, TX; 4. Utah Hematology Oncology, Ogden, UT; 5. Colorado Integrative Cancer Center, Greenwood Village, CO; 6. Baptist MD Anderson Cancer Center, Jacksonville, FL; 7. Women's Health and Healing of the Palm Beaches, Palm Springs, FL; 8. Johns Hopkins University, Baltimore, MD; 9. Magee-Women's Hospital and the Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA; 10. AMITA Health, Saint Alexius Medical Center, Bartlett, IL; 11. Sparrow Regional Cancer Center, Lansing, MI; 12. Rocky Mountain Cancer Center – Littleton, Littleton, CO; 13. Piedmont Cancer Institute, Fayetteville, GA; 14. Texas Oncology-Baylor Sammons Cancer Center, US Oncology, Dallas, TX; 15. Vail Health Shaw Regional Cancer Center, Edwards, CO; 16. Akron General Medical Center, Akron, OH; 17. Comprehensive Cancer Center, Palm Springs, CA; 18. Medical Affairs, Agendia Inc., Irvine, CA

FLEX ENROLLMENT REACHES 10,000 IN FIVE YEARS



250+ Enrolling physicians



28 abstracts published in US Scientific congresses



38 studies in progress



800 clinical data points from customized CRFs


FLEX: ongoing, multi-center trial (NCT03053193) began in the United States in 2017

Enrollment target: 30,000 patients


Primary objective: create a large-scale collaborative registry of early-stage breast cancer patients that links comprehensive clinical and full genome expression data to reveal new prognostic and/or predictive gene signatures.

Secondary objective: Empowering FLEX investigators with a shared infrastructure database and investigator-initiated studies to expand knowledge of Early Breast Cancer with a resource friendly approach.


ENROLLMENT AT A GLANCE




FLEX STUDY NETWORK




BluePrint Molecular Subtypes




Clinical Grade




MammaPrint Risk Results



Menopausal Status



TREATMENT & FOLLOW-UP



INVESTIGATOR-INITIATED STUDY TOPICS

The FLEX platform has been used to address a wide array of research questions, from quality-of-life studies to differential gene expression analyses. The FLEX Study provides a unique access high-caliber data regardless for all FLEX physicians.

